Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system. The roles of immune checkpoints, inflammatory and angiogenesis factors, as well as circulating immune cells will be elucidated. Additionally, our investigation extends to the exploration of long non-coding RNAs (LncRNAs) and genes associated with the coagulation vascular system. Initially, these aspects will be evaluated in the context of colorectal cancer, with the intention to expand our research to other solid tumors.

The identification of these biomarkers and genetic factors holds the potential to revolutionize therapeutic approaches for patients with cancer-associated thromboembolism, shedding light on their chemotherapy resistance. The effectiveness of combining immunotherapy with targeted inhibitors like Palbociclib and anticoagulants such as Rivaroxaban, among other potential interventions, will be assessed.

This study aims to make significant contributions to the understanding of these critical aspects, ultimately leading to the development of more effective treatment strategies for cancer patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lebanese University
• Collaborator: Haykel Hospital
• Treatments: Palbociclib; Rivaroxaban

Criteria

Inclusion Criteria:

• Individuals of white ethnicity.

• Age between > 18

• Both males and females.

• Diagnosis of selected cancer type (e.g., colorectal cancer).

• Cancer stage 0/I/II without metastasis or lymph node dissemination at the time of enrollment.

• No previous cancer therapy (radiotherapy, chemotherapy, or immunotherapy) received before study enrollment.

• Unrelated patients.

Exclusion Criteria:

• Cancer stage III/IV.

• History of hematological cancer types or previous cancers, recurrent or relapse.

• Diagnosis of inflammatory bowel diseases.

• Pre-existing cardiovascular diseases or coronary artery diseases.

• Confirmed treated or untreated autoimmune diseases.

• Metabolic disorders, diabetes, or hypertension.

• Neurological diseases.

• Evidence of cardiac, renal, bone, or cerebral damage.

• Presence of more than one type of malignancies.

• Active infections or myositis.

• Familial polyposis.

• Alcohol or smoking habits.

• Colon-affecting food allergies.

• Body mass index (BMI) >30.

• Significant weight loss within the last 2 years.

• History of abdominal surgeries.

• Pregnancy.

• Related patients.